FDA

Pills

Why 1 Analyst Sees Over 50% Upside in Sarepta

Sarepta Therapeutics Inc. (NASDAQ: SRPT) received a favorable rating from Merrill Lynch, and as a result the stock was climbing in Tuesday’s trading session. The firm raised its rating to ...
Read Full Story »
Pills

Is a Generic Nexium Purple Pill for You?

When it comes to drugs being overly advertised, the Purple Pill, or Nexium, has been advertised over and over for years now. Now the question to ask is if a ...
Read Full Story »
cannabis

GW Cannabinoid Drug Fails Cancer Pain Trial

GW Pharmaceuticals PLC (NASDAQ: GWPH) and Otsuka Pharmaceutical Development & Commercialization reported top-line results from the first of three Phase 3 trials for Sativex. The drug candidate is an investigational ...
Read Full Story »
Pills

Is a Generic Diovan for You?

Many investors have to worry about the so-called patent cliff in pharmaceutical companies. Generic launches are often priced into most analyst estimates, but these generic launches are always important to ...
Read Full Story »
downgrade sign

Analysts Predict Big Value Trap for Gilead Investors

AbbVie Inc. (NYSE: ABBV) and Express Scripts Holding Co. (NASDAQ: ESRX) entered into an exclusive distribution agreement following the U.S. Food and Drug Administration’s (FDA) approval of AbbVie’s hepatitis C ...
Read Full Story »
Pills

What the AbbVie and Express Script Deal Means for Gilead

AbbVie Inc. (NYSE: ABBV) received U.S. Food and Drug Administration (FDA) approval for its hepatitis C drug last Friday, and the drug will directly compete with treatments from Gilead Sciences Inc. ...
Read Full Story »
fda_logo

Is a Biosimilar (Generic) Top Cancer Drug for You?

There has been a movement to get generic pharmaceutical drugs to market with for years. The notion of "biosimilars" has grown as well. Effectively this is making biotech drugs into ...
Read Full Story »
Pfizer logo

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, Celebrex now has a generic competitor in America. The drug company Actavis PLC (NYSE: ACT) announced on Wednesday that it ...
Read Full Story »
DNA

Array BioPharma: When Losing a Partnership Is Good News

Array BioPharma Inc. (NASDAQ: ARRY) announced Wednesday after the market close that it had reached a definitive agreement with Novartis A.G. (NYSE: NVS) to regain full worldwide rights to cancer ...
Read Full Story »
Pills

Are Avanir Shareholders Getting Enough in the Buyout?

Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) announced that it has entered into a definitive agreement with Japan’s Otsuka Pharmaceutical for a $17.00 per share buyout. Monday’s closing price was $15.00. After ...
Read Full Story »
145922793

Is This the Sunesis Resurrection?

In early October, Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) announced that its Phase 3 clinical trial of vosaroxin and cytarabine failed to meet the primary endpoint of the study, which ultimately ...
Read Full Story »
biotech

What Licensing Imetelstat Will Mean for Geron

Geron Corp. (NASDAQ: GERN) has announced that it entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat. What investors need to keep ...
Read Full Story »
fda_logo

Is Geron Back From the Dead?

The U.S. Food and Drug Administration (FDA) gave Geron Corp. (NASDAQ: GERN) some good news Monday morning when it removed the clinical hold on the company’s investigational new drug application ...
Read Full Story »
152498601

Pain Therapeutics and Durect Stung by Pfizer Move

Pain Therapeutics Inc. (NASDAQ: PTIE) shares dropped significantly in Monday’s trading on news that Pfizer Inc. (NYSE: PFE) had discontinued its agreement to develop and commercialize Pain’s Remoxy extended release ...
Read Full Story »
fda_logo

Sarepta Faces Major Hurdle, and Not From Ebola

In non-Ebola related news, Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot. The stock ...
Read Full Story »